Sun Pharmaceutical Industries will be reporting its earnings for the September quarter (Q2FY26) on Wednesday 05 November.

The company is expected to post steady topline growth, though profitability may remain under pressure, according to a CNBC-TV18 poll.

Overall revenue is likely to rise 7% year-on-year, while EBITDA may increase by 3%. Margins are expected to contract by around 100 basis points, and net profit could decline by about 2%, the poll showed.

On a segmental basis, US sales are expected to grow 2-3% sequentially to around $486 million, according to estimates by Kotak Institutional Equities. Global specialty sales are likely to rise 5-6% sequentially, led by the company’s key products Leqselvi and Ilumya, both of which continue to drive specialty portfolio growth.

In the In

See Full Page